Krystal Biotech, Inc.
KRYS US
KRYS USKrystal Biotech, Inc.
United States Composite161.10
USD
+0.87
(+0.54%)
Company Description
- CEO
- Mr. Krish S. Krishnan M.B.A., M.S.
- Full Time Employees
- 229
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 2100 Wharton Street Pittsburgh PA United States 15203
- CIK
- 0001711279
- Website
- www.krystalbio.com
- Business
- Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). The company also develops KB105, which is in Phase 1/2 clinical trials for treating patients with deficient autosomal recessive congenital ichthyosis; KB104 for treating netherton syndrome; KB407 that is in Phase 1 clinical trials for treating cystic fibrosis; KB707 that is in Phase 1 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.